ad image

Q12024

1 / 2
Building a Regulatory Roadmap for IND, NDA, and BLA
IND, NDA, and BLA

Building a Regulatory Roadmap for IND, NDA, and BLA

Rebecca Lamb-Wharton, Ph.D.; Brenda Schlenk, RPh; Mamadou Diallo, PharmD

PAO-03-24-CL-10Mar 26, 2024
Small Molecule API Discovery and Development Trends
Nice Insight API Report

Small Molecule API Discovery and Development Trends

April Stanley, MS MBA

Nice Insight

PAO-03-24-NI-01Mar 21, 2024
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
mRNA–LNP Manufacturing

The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles

Antonio Costa, Ph.D.; William Pasek

DIANT Pharma

PAO-03-24-CL-08Mar 18, 2024
Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool
Radioconjugate development

Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI

PAO-03-24-CL-07Mar 15, 2024
A Viral Vector CDMO Vision that Resonates
Viral Vectors

A Viral Vector CDMO Vision that Resonates

Drew Brennan; Chris Berger; Elie Hanania, Ph.D.; Dave Ingamells; Rami Barghout, PE

Avid Bioservices

PAO-03-24-CL-06Mar 14, 2024
Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development
Analytical Method Development

Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development

Xuemei Han, Ph.D.

Tanvex CDMO

PAO-03-24-CL-09Mar 13, 2024
Leveraging Decentralized Clinical Trial Strategies to Reduce Health Care Disparities
Clinical Trials Representation

Leveraging Decentralized Clinical Trial Strategies to Reduce Health Care Disparities

Jennifer Urwongse

PAO-03-24-CL-05Mar 13, 2024
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Pharma's Almanac

PAO-03-24-CL-03Mar 08, 2024
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Accelerating Product Development

What strategies are being employed to accelerate product development and commercialization without compromising quality?

Pharma's Almanac

PAO-03-24-CL-02Mar 08, 2024
Accelerating the Development and Production of High-Quality Bispecific Antibodies
Bispecific Antibodies

Accelerating the Development and Production of High-Quality Bispecific Antibodies

Dongyoung Park

Samsung Biologics

PAO-03-24-CL-01Mar 04, 2024
Pediatric Clinical Trials: Considerations for Enrollment and Retention
Pediatric Clinical Trials

Pediatric Clinical Trials: Considerations for Enrollment and Retention

Susan McCune, M.D.; Anusha Streubel, M.D.; Elizabeth Donahue

PAO-02-24-CL-04Mar 01, 2024
Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform
Digital Pathology

Advancing Disease Research and Drug Development on an Enterprise Pathology Software Platform

Nathan Buchbinder

Proscia

PAO-01-24-CL-2Feb 29, 2024
Wheeler Bio
Portable CMC

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Wheeler Bio

PR-M02-29-01Feb 29, 2024
Right from the Start: Designing Advanceable Formulations and Processes at Phase I
Advanceability

Right from the Start: Designing Advanceable Formulations and Processes at Phase I

Serán Bioscience

PAO-02-24-CL-09Feb 26, 2024
Exploring New Possibilities with 3D Printing of Pharmaceuticals
3D Printing

Exploring New Possibilities with 3D Printing of Pharmaceuticals

Thomas Kipping, Ph.D.

MilliporeSigma

PAO-02-24-CL-11Feb 23, 2024
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

Julie Trulson, Ph.D.

PAO-02-24-CL-07Feb 15, 2024
Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies
Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

Julie Trulson, Ph.D.

PAO-02-24-CL-06Feb 15, 2024
Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform
Biologics Formulation

Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform

Pawel Stanczak, Ph.D.

Tanvex CDMO

PAO-02-24-CL-02Feb 15, 2024
The Translational Index Score: Improving the Entire Drug Development Cycle
Translation

The Translational Index Score: Improving the Entire Drug Development Cycle

Jo Varshney, Ph.D., D.V.M.

PAO-02-24-CL-10Feb 15, 2024
Cell-Free Protein Synthesis Holds Real Potential to Transform Drug Development and Manufacturing
Cell-Free

Cell-Free Protein Synthesis Holds Real Potential to Transform Drug Development and Manufacturing

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-02-24-NI-01Feb 14, 2024
1 / 2